SCHEMBL5953372

SCHEMBL5953372

CCOc1cccc(C(F)(F)F)c1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.71
MAPK1 P28482 1/20 0.59
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAOB P27338 2/20 0.53
AOC3 Q16853 1/20 0.53
MAPT P10636 2/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
NPY1R P25929 1/20 0.52
LMNA P02545 2/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
PKM P14618 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ATM Q13315 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12072717 0.86 L3MBTL1 (0.60) L3MBTL1MAPK1KDM4EMAOBAOC3
SCHEMBL12251531 0.85 L3MBTL1 (0.55) L3MBTL1MAPK1KDM4ETP53CYP3A4
SCHEMBL171811 0.85 L3MBTL1 (0.68) L3MBTL1KDM4EMAOBAOC3MAPT
SCHEMBL2429378 0.84 L3MBTL1 (0.66) L3MBTL1KDM4EALDH1A1GAALMNA
SCHEMBL8773193 0.83 MAPK1 (0.61) L3MBTL1MAPK1KDM4EMAPTALDH1A1
SCHEMBL30167649 0.82 L3MBTL1 (0.55) L3MBTL1KDM4EMAOBAOC3MAPT
SCHEMBL5619009 0.82 CYP3A4 (0.55) L3MBTL1MAPK1KDM4ETP53CYP3A4
SCHEMBL29979999 0.82 CYP3A4 (0.55) L3MBTL1MAPK1KDM4ETP53CYP3A4
SCHEMBL22221774 0.82 L3MBTL1 (0.64) L3MBTL1KDM4EALDH1A1GAALMNA
SCHEMBL11512115 0.82 L3MBTL1 (0.56) L3MBTL1MAPK1KDM4EMAOBAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023226102-A1 DESIGN, PREPARATION AND USE OF NOVEL MACROLIDE 上海彩迩文生化科技有限公司 2023-11-30 WO disclosed
US-20230337672-A1 METHOD OF CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE TO QoI FUNGICIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-10-26 US disclosed
US-20230337672-A1 METHOD OF CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE TO QoI FUNGICIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-10-26 US disclosed
US-20230232827-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-27 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
EP-3461484-B9 DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS AERIE PHARMACEUTICALS INC (US) 2021-06-09 EP disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 US disclosed
CN-105916843-B Octahydrocyclopenta [ c ] pyrrole selective NR2B negative regulator 科登特治疗公司 2019-09-20 CN disclosed
EP-2970303-B3 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2018-08-01 EP disclosed
US-10000483-B2 Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-19 US disclosed
WO-2007127639-A2 PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE AERIE PHARMACEUTICALS, INC. (US) 2007-11-08 WO disclosed
US-20070254920-A1 Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use AERIE PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
CN-1300073-C Preparation method of 3,3'-di(trifluouro methyl) phenyl methane SHISIHEWEI CHEMICAL CO LTD SHA (CN) 2007-02-14 CN disclosed
US-7070838-B2 Liquid crystalline compound, liquid crystal composition and their polymers CHISSO PETROCHEMICAL CORPORATION (JP) 2006-07-04 US disclosed
CN-1651372-A Preparation method of 3,3'-di(trifluouro methyl) phenyl methane SHISIHEWEI CHEMICAL CO LTD SHA (CN) 2005-08-10 CN disclosed
US-20050007541-A1 Liquid crystalline compound, liquid crystal composition and their polymers JNC PETROCHEMICAL CORPORATION (JP) 2005-01-13 US disclosed
EP-0511826-B1 Phosphosulfonate herbicides ROHM & HAAS (US) 1997-07-16 EP disclosed
US-5500405-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1996-03-19 US disclosed
US-5272128-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1993-12-21 US disclosed
EP-0511826-A2 Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1992-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 L3MBTL1 3224/4885MAPK1 2346/4885KDM4E 972/4885
US-10000483-B2 Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof BMX, MELK, TEC L3MBTL1 2181/4885MAPK1 144/4885KDM4E 2317/4885
US-20070254920-A1 Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use HCAR1, HCAR2, PAICS L3MBTL1 4086/4885MAPK1 2182/4885KDM4E 3612/4885
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 L3MBTL1 3583/4885MAPK1 4465/4885KDM4E 2167/4885
US-20230337672-A1 METHOD OF CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE TO QoI FUNGICIDE CYC1, SQOR, MT-CO1 L3MBTL1 1545/4885MAPK1 1718/4885KDM4E 1417/4885
US-20230232827-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES CYC1, SQOR, MT-CO3 L3MBTL1 1321/4885MAPK1 2140/4885KDM4E 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.